Article Text

Download PDFPDF
Clinical characteristics–other
L02 Insulin sensitivity and early-phase insulin secretion in normoglycemic patients with huntington's disease
  1. CV Russo1,
  2. E Salvatore1,
  3. T Tucci1,
  4. C Rinaldi1,
  5. M Massarelli1,
  6. P Sorrentino1,
  7. F Rossi1,
  8. LD Maio1,
  9. A Filla1,
  10. A Colao2,3,
  11. G De Michele1
  1. 1Department of Neurological Sciences, Federico II University, Naples, Italy
  2. 2Department of Molecular and Clinical Endocrinology, Federico II University, Naples, Italy
  3. 3Department of Oncology, Federico II University, Naples, Italy

Abstract

Background Huntington's Disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanded CAG repeat in exon 1 of the HTT gene. Apart from neurological impairment, there is increasing evidence pointing towards an early involvement of the endocrine system in HD. Recent studies, conducted to investigate the association with increased risk of diabetes mellitus and with impairment in insulin sensitivity and secretion in HD patients, led to contradictory results.

Aims To investigate glucose homeostasis in HD by performing an oral glucose-tolerance test (OGTT) to evaluate the glucose-tolerance status and OGTT-related insulin release.

Patients and Methods Twenty-eight consecutive patients with HD and 28 healthy controls were matched for age, sex, and BMI. Diagnosis of HD was confirmed in all patients by analysis for the CAG repeat expansion. Clinical assessment of patients was performed using the Unified Huntington's Disease Rating Scale (UHDRS) motor section and the Total Function Capacity (TFC). Wide basal metabolic investigations and a 2 h 75-g OGTT were performed. We used the homeostasis model assessment of insulin resistance (HOMA-IR) as index of insulin sensitivity. Insulin secretion was determined by the insulinogenic index.

Results HD patients did not differ from the control group with respect to fasting plasma glucose level, insulin sensitivity and secretion. However, in comparison with controls HD patients showed lower serum glucose (−19%) and insulin levels (−48%) 30 min. after oral glucose load and higher serum insulin levels at 90 (+132%) and 120 min. (+380%). CAG expansion size, disease stage, or BMI did not influence HOMA-IR and insulinogenic index in HD patients.

Conclusions Our data challenge the assumption of an increased risk of diabetes among HD patients although they suggest abnormal glucose regulation.

  • Glucose tolerance test
  • insulin sensitivity
  • insulin resistence

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.